Pharmafile Logo
Pharmafocus logo
Advanced Search

Plavix

Showing 15 posts of 29 posts found.

finance

Sanofi lowers Q3 sales figures from 2015

October 13, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cipro, Plavix, Sanofi, financial results

Sanofi lowered its aggregate sales figure for Q3 2016 from €9.59 billion to €9.46 billion ahead of the release of …

News
Lilly image

NICE extends recommendation for Efient

July 24, 2014
Sales and Marketing ACS, Efient, NICE, Plavix, longs ton, prasugrel

In updated guidance NICE has extended its recommendation of Efient (prasugrel) in combination with aspirin for preventing blood clots in …

News
BMS image

CHMP approves six drugs including daclatasvir

June 30, 2014
Sales and Marketing BMS, CHMP, HCV, Plavix, daclatasvir, daklinza, ge

A key advisory committee for the European Medicines Agency has given its approval to six new drugs at its latest …

News
BMS image

BMS hopes for Yervoy sequel with new deal

March 18, 2014
Research and Development, Sales and Marketing Avapro, BMS, Plavix, Yervoy, five prime, immune-oncology

Bristol-Myers Squibb has announced a new research and development deal with Five Prime Therapeutics aimed at discovering potentially new cancer …

News
Sanofi’s chief executive Christopher Viehbacher image

Analysts ‘disappointed’ by Sanofi guidance

February 6, 2014
Sales and Marketing Aubagio, Plavix, Sanofi, q4, sales

Sanofi has announced a mixed bag for its full year results as analysts have questioned why its forecasts for the …

News
Sanofi image

Sanofi sales slide on patent cliff woes

August 1, 2013
Sales and Marketing Aprovel, Plavix, Q2, Sanofi

Sanofi has been hit by generic erosion for key drugs in the second quarter, but the firm is confident it …

News
BMS image

Sharp fall in sales for Bristol-Myers Squibb

July 26, 2013
Sales and Marketing Avapro, BMS, Plavix, Q2

Bristol-Myers Squibb has seen a fall in sales over the past three months as it struggles with major patent losses. …

News
sanofi image

Diabetes softens generics blow for Sanofi

October 30, 2012
Sales and Marketing Eloxatin, Plavix, Sanofi, diabetes, emerging markets, patent cliff

Sanofi has unveiled its results for the third quarter, with news that the damage done by patent expiries has not …

News
BMS image

Patent losses force change for Sanofi

October 3, 2012
Sales and Marketing Avapro, BMS, Plavix, Sanofi, patent loss

Patent expiries are behind the decision by Sanofi and Bristol-Myers Squibb to radically restructure their long-term corporate alliance. The loss …

News

Pharma is recovering, says Moody’s

September 25, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Moody's, Plavix, austerity, generics, pharma

Credit ratings agency Moody’s believes that the travails of the past few years, when various big-selling drugs went off-patent, are …

News

Efient fails to prove superiority to Plavix

August 29, 2012
Brillinta, Efient, Plavix, prasugrel, ticagrelor

Daiichi Sankyo and Lilly’s heart drug Efient has failed to come up to the mark in a late-stage trial which …

News

Plavix loses US patent protection

May 18, 2012
Sales and Marketing BMS, FDA, Lipitor, Pfizer, Plavix, Sanofi

Sanofi and Bristol-Myers Squibb’s blood thinner Plavix has lost its patent protection in the US.  The drug, which made $6.6 …

News

Dismay as Sanofi announces UK plant closure

March 15, 2012
Manufacturing and Production, Sales and Marketing Plavix, Sanofi, job losses, manufacturing

Sanofi has decided to close down a manufacturing facility in the North East of the UK with the loss of …

News
Brilique picture

Brilique recommended for use by Germany’s pricing watchdog

December 19, 2011
Sales and Marketing AstraZeneca, Brilique, Plavix

Germany’s new pricing committee has said that AstraZeneca’s Brilique is a cost effective treatment for patients with a certain heart …

News

Merck’s vorapaxar fails in late-stage trial

November 15, 2011
ACS, Brilinta, Efient, Merck, Plavix, antiplatelet, vorapaxar

Merck’s novel blood thinner vorapaxar has failed to meet its primary endpoint in a late-stage study.The TRACER trial compared vorapaxar …

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024